Sanofi SA

Sanofi: Information concerning the total number of voting rights and shares - February 2025

03 Apr 2025 14:08:15 By Nasdaq GlobeNewswire

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

03 Apr 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

28 Mar 2025 16:07:34 By Nasdaq GlobeNewswire

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

28 Mar 2025 02:00:00 By Nasdaq GlobeNewswire

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

26 Mar 2025 02:00:00 By Nasdaq GlobeNewswire

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

25 Mar 2025 02:00:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q1 2025 Aide mémoire

24 Mar 2025 02:30:00 By Nasdaq GlobeNewswire

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

20 Mar 2025 02:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

08 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

05 Mar 2025 12:10:00 By Nasdaq GlobeNewswire

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

25 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

22 Feb 2025 02:30:00 By Nasdaq GlobeNewswire

Press Release: Sanofi and CD&R sign Opella share purchase agreement

19 Feb 2025 01:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

18 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

13 Feb 2025 14:08:49 By Nasdaq GlobeNewswire

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

13 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Execution of a share buyback agreement for up to €2 billion

07 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi announces buy back of shares from L’Oréal

03 Feb 2025 01:30:00 By Nasdaq GlobeNewswire

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

31 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

30 Jan 2025 01:30:00 By Nasdaq GlobeNewswire